Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis

Abstract

Molecular events leading to epithelial ovarian cancer are poorly understood but ovulatory hormones and a high number of life-time ovulations with concomitant proliferation, apoptosis, and inflammation, increases risk. We identified genes that are regulated during the estrous cycle in murine ovarian surface epithelium and analysed these profiles to identify genes dysregulated in human ovarian cancer, using publically available datasets. We identified 338 genes that are regulated in murine ovarian surface epithelium during the estrous cycle and dysregulated in ovarian cancer. Six of seven candidates selected for immunohistochemical validation were expressed in serous ovarian cancer, inclusion cysts, ovarian surface epithelium and in fallopian tube epithelium. Most were overexpressed in ovarian cancer compared with ovarian surface epithelium and/or inclusion cysts (EpCAM, EZH2, BIRC5) although BIRC5 and EZH2 were expressed as highly in fallopian tube epithelium as in ovarian cancer. We prioritised the 338 genes for those likely to be important for ovarian cancer development by in silico analyses of copy number aberration and mutation using publically available datasets and identified genes with established roles in ovarian cancer as well as novel genes for which we have evidence for involvement in ovarian cancer. Chromosome segregation emerged as an important process in which genes from our list of 338 were over-represented including two (BUB1, NCAPD2) for which there is evidence of amplification and mutation. NUAK2, upregulated in ovarian surface epithelium in proestrus and predicted to have a driver mutation in ovarian cancer, was examined in a larger cohort of serous ovarian cancer where patients with lower NUAK2 expression had shorter overall survival. In conclusion, defining genes that are activated in normal epithelium in the course of ovulation that are also dysregulated in cancer has identified a number of pathways and novel candidate genes that may contribute to the development of ovarian cancer.

A Novel Candidate Gene for Temperature-Dependent Sex Determination in the Common Snapping Turtle

“…In Xenopus, CIRBP displays nucleocytoplasmic shuttling and has distinct roles in each cellular compartment (Aoki et al 2002). Nuclear CIRBP is associated with cell growth and differentiation (Lleonart 2010;Emmanuel et al 2011;Masuda et al 2012). In response to various environmental stressors, CIRBP moves from the nucleus to the cytoplasm where it associates with stress granules to regulate RNA metabolism (Yang and Carrier 2001;De Leeuw et al 2007).…”

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

“…1 Although 90% of patients with ovarian cancer initially respond to a frontline approach of cytoreductive surgery and platinum-based chemotherapy, most patients ultimately relapse. 2 Pegylated liposomal doxorubicin (PLD) is approved for treatment of ovarian cancer after failure of platinum-based therapy and can be used as a platform for novel combination regimens.…”

In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans

“…We generated a list of OVC-specific genes in humans that were known to be differentially expressed from three sources: TCGA study [31], Polanski et al [29], and Emmanuel et al [32]. Five genes significantly upregulated in Table 1 are also upregulated in human OVC including B2M, CLDN, EPCAM, S100A6, and TPD52.…”